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Abstract
● AIM: To investigate the efficacy and safety of ranibizumab 
(RZB group) and dexamethasone implant (DEX group) 
intravitreal treatments in patients with treatment-naïve 
center involved diabetic macular edema (DME) by means 
of functional and morphological assessments.
● METHODS: This retrospective cohort study included 50 
eyes of 50 patients with DME treated either with RBZ or DEX. 
Best-corrected visual acuity (BCVA) and microperimetry 
were evaluated at baseline and during a 6-month follow-up. 
In addition, central macular thickness (CMT) by means of 
structural optical coherence tomography (OCT) and retinal 
capillary plexus density and choriocapillary density by 
means of OCT angiography were assessed in all cases.
● RESULTS: Functional and morphological parameters 
significantly improved during the study period in both 
groups. BCVA improved significantly in both groups with 
a greater increase in the DEX group compared to the RBZ 
group (P=0.030). Microperimetry significantly differed 
during follow-up between the two treatments (P=0.031). 
In both groups CMT significantly decreased (P<0.001) 
without statistically significant differences between the 
two groups. A statistically significant increase of deep 
capillary plexus density was detected in both groups at 
30d after therapy. The retreatment rate was 0.70±0.10 and 
0.65±0.10 in the RBZ group and 0.65±0.10 and 0.50±0.11 
in DEX group at 120 and 180d respectively. Two out of 
25 patients in DEX group showed intraocular pressure 
increase requiring hypotonic eye drops.
● CONCLUSION: Both treatments are very effective for 
DME treatment during 6mo of follow-up with a lower 
retreatment rate in DEX group.
● KEYWORDS: optical coherence tomography angiography; 
diabetic macular edema; intravitreal dexamethasone implant; 
intravitreal ranibizumab injections
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INTRODUCTION
D iabetic macular edema (DME) is a leading cause of visual impairment in diabetic retinopathy (DR) and may 
occur at any stage of the disease[1-2].
In the past laser photocoagulation demonstrated its efficacy 
in prevention of vision loss but did not always consistently 
improve visual acuity[3]. Nowadays, intravitreal treatment 
either with anti-vascular endothelial growth factor (VEGF) or 
steroids agents has become among the most used and effective 
therapy for DME condition due to their effect on the retinal 
vascular permeability and anti-inflammatory action[4-8].
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Anti-VEGF intravitreal treatment is considered a first-line 
therapy for center-involved DME improving visual acuity in a 
large percentage of patients with best visual results in monthly 
fixed regimen compared to pro re nata (PRN) regimen clinical 
trials[9-12]. Dexamethasone intravitreal implant (DEX) has 
demonstrated its efficacy in DME and has been proposed 
as a second line therapy in DME refractory to anti-VEGF 
treatments. Recently some reports reported DEX use and 
efficacy in treatment naïve DME[13-17].
The aim of the study was to investigate the efficacy and safety 
of the intravitreal ranibizumab (RZB) treatment and the DEX 
in treatment-naïve DME patients by means of a functional and 
morphological retrospective study. A comparison between both 
groups of treatments, in terms of qualitative and quantitative 
parameters was performed.
SUBJECTS AND METHODS
Ethical Approval  This retrospective cohort study included 
fifty eyes of 50 patients with center involved DME treated at 
the Ophthalmologic Clinic of University “G. d’Annunzio”, 
Chieti-Pescara, Italy between December 2016 and October 
2017. This retrospective observational study adhered to the 
tenets of the Declaration of Helsinki and our Institutional 
Review Board approved the retrospective consecutive chart 
review. Written informed consent was obtained from all 
subjects enrolled.
The inclusion criteria were: 1) treatment naïve patients with 
no proliferative moderate DR stage (simplified version of 
the ETDRS classification)[18] and center-involved DME 
type without subretinal fluid component; 2) central macular 
thickness (CMT) >300 µm as measured using the spectral-
domain optical coherence tomography (SD-OCT) at the 
baseline examination; 3) age >18y; 4) best corrected visual 
acuity (BCVA) greater than 0.5 logMAR in the study eye at 
baseline examination; 5) treatment with RBZ or DEX implant. 
If both eyes of a patient met the inclusion/exclusion criteria, 
the eye with higher CMT was selected as the study eye.
The patients treated with RZB (Lucentis, Genentech, Inc., 
South San Francisco, California, and Novartis Pharma AG, 
Basel, Switzerland), were included if three consecutive 
monthly intravitreal injections of 0.5 mg ranibizumab followed 
by PRN regimen had been administered.
The patients treated with DEX were included if an intravitreal 
implant of 0.7 mg sustained-release dexamethasone (DEX 
implant; Ozurdex, Allergan, Irvine, CA, USA) followed by 
PRN treatment, administered not before 4mo from the first 
implant had been administered during a 6-month follow-
up. PRN regimen consisted of a new injection starting from 
month 3 in RBZ group and from month 4 in DEX group, in 
patients with recurrence/persistence of DME (CMT>300 µm) 
associated or not with loss of BCVA.
The exclusion criteria were: 1) any previous ocular surgery in 
the last 6mo; 2) laser treatments; 3) retinal vascular diseases; 
4) medium lens opacities according to Lens Opacities 
Classification System (LOCS)[19]. 
All patients were diagnosed with DR and DME using 
fundoscopy examination, fluorescein angiography (FA), SD-
OCT and were evaluated with a comprehensive ophthalmologic 
examination. 
CMT using SD-OCT (XR Avanti®; Optovue, Inc., Fremont, 
CA, USA), foveal and parafoveal vessel density using optical 
coherence tomography angiography (OCTA; XR Avanti® 
AngioVue, Optovue Inc., Fremont, CA, USA, SSADA 
software version 2017.1.0.144)[20-22], BCVA and microperimetry 
(MP; MP-1 Microperimeter, Nidek Technologies, Padova, 
Italy) were assessed at baseline, 30, 60, 90, 120, 150 and 180d 
after the first intravitreal injection of ranibizumab and DEX 
implant.
SD-OCT Angiography with XR Avanti  The XR Avanti 
AngioVue OCTA is a device with a high speed of 70 000 axial 
scans per second that uses a light source of 840 nm and an 
axial resolution of 5 μm. This system is based on the SSADA 
algorithm (version 2017.1.0.144), which uses blood flow as 
intrinsic contrast. Flow is detected as a variation over time in a 
speckle pattern formed by the interference of light scattered by 
red blood cells and adjacent tissue structures. 
OCTA scans were acquired following a standardized protocol 
as previously described[23].
Vascular Layer Segmentation  Vascular retinal layers were 
visualized and segmented as previously described in the 
superficial capillary plexus (SCP), the deep capillary plexus 
(DCP) and the choriocapillaris (CC)[24]. 
The projection-resolved algorithm was used to remove 
projection artifacts from the inner vascular plexus in the deep 
vascular plexus. This algorithm retains flow signals from blood 
vessels while suppressing projected flow signals in deeper 
layers. Images were reviewed by two investigators (Toto L 
and D’Aloisio R) for segmentation accuracy; if segmentation 
errors were observed, then they were corrected using the 
segmentation and propagation tool from AngioVue. (Angiovue, 
Optovue, Freemont CA, USA). Final images were reviewed 
again to confirm segmentation placement in all B-Scans.
Quantitative Vessel Analysis  Objective quantification of 
vessel density was carried out for each eye using SSADA 
software. A quantitative analysis was performed on the OCTA 
en-face images for each eye using AngioVue software as 
previously described[23].
Vessel densities of the SCP, DCP and CC were automatically 
calculated by software on OCTA 3×3-mm volume scans in the 
whole foveal and parafoveal area, foveal area, parafoveal area 
and in the superior and inferior hemi-macular areas. Vessel 
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density was defined as the percentage of the area occupied 
by vessels in a circular region of interest (ROI) of 3 mm in 
diameter positioned on the center of the foveal avascular zone 
and including the foveal area (1 mm of diameter) and the 
parafoveal area, which constitute the remaining part inside the 
ROI. 
Foveal and Parafoveal Retinal Thickness Analysis  Foveal 
and parafoveal macular thickness from the internal limiting 
membrane (ILM) to the retinal pigment epithelium (ILM-
RPE) were automatically calculated by software on OCTA 
3×3-mm volume scans (XR Avanti1; Optovue, Inc., Fremont, 
CA, USA). A circular ROI centred on the foveal avascular 
zone with a diameter of 3.0 mm was used for retinal thickness 
analysis: the central foveal area (1 mm in diameter) and the 
parafoveal area constituted the remaining part inside the 
ROI (full parafoveal area or parafoveal area in the temporal, 
superior, nasal and inferior quadrants). 
Sample Size Determination and Statistical Analysis  The 
estimation of the number of eyes was based on the main 
endpoint criteria.  A planned sample size of 40 patients was 
expected to provide 80% power for a two-sided test with 
significance level of 0.05, assuming an effect size of 17% in 
difference of BCVA after seven days of implantation with 
between subjects’ pooled standard deviation of 0.3 logMAR.
A Shapiro-Wilk’s test was performed to evaluate the departures 
from normality distribution for each variable. Student’s test was 
performed to compare quantitative parameters between DEX 
and RZB group. Analysis of variance (ANOVA) for repeated-
measures with linear trend analysis was performed to evaluate 
the effect of time (within factor), type of therapy (between factor) 
and interaction separately for each quantitative parameter. 
The Kaplan-Meier method was applied to estimate the re-
treatment rates stratified respect to treatment group (DEX vs 
RBZ). The false discovery rate (FDR) correction was used to 
control the family-wise type I error rate and an FDR adjusted 
P value less than 0.05 was determined to be statistically 
significant. Statistical analysis was performed using IBM® 
SPSS Statistics version 20.0 software (SPSS Inc., Chicago, 
Illinois, USA).
RESULTS
Demographic Data  A total of 50 patients were enrolled in 
this study from December 2016 throughout October 2017. 
Totally 25 eyes of 25 type 2 diabetic patients (RZB group, 
13 males; 12 females; mean age of 61.4±7.3y) with DME 
treated with 3 monthly ranibizumab injections followed by a 
PRN regimen and 25 eyes of 25 type 2 diabetic patients (DEX 
group, 10 males; 15 females; mean age of 62.1±6.8y) with 
DME treated with one DEX followed by a PRN treatment, 
were evaluated for the analysis (P=0.752 and P=0.755 for 
gender and age, respectively). 
No treatment-related complications were observed during the 
follow-up, except for two patients of DEX group that showed 
intraocular pressure increase requiring hypotonic eye drops.
Thirteen out of 25 eyes in the RZB group and fourteen out of 
25 eyes, in the DEX group were pseudophakic. 
Functional Parameters at Baseline  The mean BCVA and 
4° MP values of the two groups of patients at the baseline are 
reported in Table 1. 
No statistically significant difference was found between 
the two groups of patients in terms of BCVA (P=0.120) and 
microperimetry sensitivity (P=0.948). The mean BCVA at 
the baseline was 0.4±0.3 logMAR in the RZB group and 
0.5±0.1 logMAR in the DEX group (Table 1). The mean 
microperimetry sensitivity at the baseline was 5.7±5.5 dB in 
the RZB group and 5.8±5.3 dB in the DEX group (Table 1).
Morphological Parameters at Baseline  At the baseline no 
statistically significant difference was found between the RZB 
group and DEX group in terms of morphological parameters 
Table 1 Baseline parameters of patients
Variable
RZB group
(n=25)
DEX group
(n=25)
Pa
CMT (µm)
Fovea 460.3±125.2 479.1±100.6 0.561
Parafovea 412.8±73.1 447.7±76.0 0.104
SCPD (µm)
Whole 39.8±4.4 40.1±4.2 0.806
Fovea 26.8±5.8 29.3±5.2 0.115
Parafovea 41.5±4.9 41.3±4.3 0.878
Parasuperior 41.3±5.1 40.0±5.8 0.404
Parainferior 40.8±5.0 41.0±6.1 0.899
DCPD (µm)
Whole 45.9±5.1 45.4±5.1 0.730
Fovea 20.7±7.7 19.8±7.4 0.675
Parafovea 47.7±4.9 48.3±3.9 0.634
Parasuperior 48.8±4.9 46.5±6.0 0.144
Parainferior 47.7±3.9 47.5±5.0 0.875
CCD (µm)
Whole 61.3±7.0 63.0±1.8 0.254
Fovea 61.4±6.2 60.8±5.7 0.723
Parafovea 61.5±6.0 63.0±3.3 0.279
Parasuperior 59.9±8.8 62.0±2.1 0.252
Parainferior 61.5±6.3 62.0±3.3 0.727
4° MP (dB) 5.7±5.5 5.8±5.3 0.948
BCVA (logMAR) 0.4±0.3 0.5±0.1 0.120
aStudent’s t-test DEX group vs RZB group; CMT: Central macular 
thickness; SCPD: Superior capillary plexus density; DCPD: Deep 
capillary plexus density; CCD: Choriocapillaris density; MP: 
Microperimetry; BCVA: Best corrected visual acuity. Data are 
expressed as mean and standard deviation.
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(Table 1). The mean CMT in the foveal area was 460.3±125.2 μm 
(RZB group) and 479.1±100.6 μm (DEX group) (Table 1). 
The mean superficial capillary plexus density (SCPD), the 
mean deep capillary plexus density (DCPD) and the mean 
choriocapillaris density (CCD) were not significantly different 
(Table 1).
Post Treatment Analysis  During the entire follow-up 
period BCVA improved significantly in both groups with 
a greater increase in the DEX group compared to the RBZ 
group (P=0.030; Table 2). Variation of retinal sensitivity at 
microperimetry significantly differed during follow-up between 
the two treatments (P=0.031).
In both groups CMT significantly decreased (Table 2; 
P<0.001) in the foveal and parafoveal area without statistically 
significant differences between the two groups (Figure 1). 
In the RZB group CMT in the foveal area significantly 
decreased at the postoperative controls from 460.3±125.2 μm 
to 342.1± 65.8 μm at 30d and 322.8±55.6 at 60d and in the 
parafoveal area from 412.8±73.1 μm to 354.7±33.5 μm at 30d 
and 350.2±30.3 μm at 60d (Table 2 and Figure 1).
In the DEX group CMT in the foveal area significantly 
decreased at the postoperative controls from 479.1±100.6 μm 
to 302.7±49.1 μm at 30d and 284.2±49.6 μm at 60d and in the 
parafoveal area from 447.7±76.0 μm to 348.8±24.1 μm at 30d 
and 345.2±22.4 μm at 60d (Table 2 and Figure 1). 
At 90 and 120d after injection, central foveal and parafoveal 
thickness continued to decrease (Table 2 and Figure 1). At 
6-month follow-up, foveal CMT was 250.2±28.7 μm and 
300.1±26.7 μm respectively in RZB and DEX groups and 
the parafoveal CMT was 330.5±25.3 μm and 357.3±23.9 μm 
respectively in RZB and DEX groups. Overall, SCPD did not 
modify significantly during the follow-up in both groups, 
while a difference was found between the two groups of 
treatment regards to parainferior SCDP (P=0.023; Figures 2, 
3, Table 3).
A statistically significant increase in foveal DCPD was 
detected in both groups at 30d after therapy (Table 3; P<0.001). 
At 6-month follow-up both groups showed a significant rise 
in foveal DCPD from the baseline (from 19.8±7.4 μm to 
27.7±7.4 μm in DEX group; from 20.7±7.7 μm to 27.4±7.0 μm 
in RZB group; Figures 2, 3).
Overall, no statistically significant difference in CCD was 
detected during the follow-up and between the two types of 
treatment (Table 3; Figures 2, 3).
The percentage of patients requiring retreatment during follow-
up was different between the two groups at different follow-
up controls. The 120- and 180-day re-treatment rates were 
0.70±0.10 and 0.65±0.10 respectively, for patients in the RBZ 
group and 0.65±0.10 and 0.50±0.11, respectively, for patients 
in DEX group (Figure 4).
Table 2 Two-way ANOVA for repeated measures of morphological and functional parameters from baseline to 180d after therapy
Variable Group Baseline 30d 60d 90d 120d 150d 180d Pa Pb Pc
No. of eyes (DEX/RZB group) 25/25 25/25 25/25 25/12 14/12 13/10 13/9
CMT (µm)
Fovea DEX group 479.1±100.6 302.7±49.1 284.2±49.6 306.4±51.7 292.7±21.0 299.0±31.4 300.1±26.7 <0.001d 0.091 0.920
RZB group 460.3±125.2 342.1±65.8 322.8±55.6 319.5±98.4 249.0±33.1 256.5±41.7 250.2±28.7
Parafovea DEX group 447.7±76.0 348.8±24.1 345.2±22.4 360.5±30.4 350.0±14.1 355.4±16.7 357.3±23.9 <0.001d 0.567 0.039
RZB group 412.8±73.1 354.7±33.5 350.2±30.3 345.8±34.9 324.6±24.0 327.4±31.0 330.5±25.3
4° MP (dB) DEX group 5.8±5.3 7.9±4.4 7.9±4.3 7.6±5.2 6.4±5.5 6.5±5.4 7.0±5.9 0.126 0.122 0.031d
RZB group 5.7±5.5 4.5±3.6 6.0±4.4 5.4±4.1 5.8±3.8 5.9±4.0 5.8±4.5
BCVA (logMAR) DEX group 0.5±0.1 0.4±0.2 0.3±0.2 0.3±0.2 0.3±0.2 0.3±0.2 0.3±0.1 <0.001d 0.030 <0.001d
RZB group 0.4±0.3 0.3±0.2 0.3±0.2 0.3±0.2 0.3±0.4 0.3±0.3 0.3±0.4
Data are expressed as mean and standard deviation. CMT: Central macular thickness; aP-value relative to effect of period; bP-value relative to 
effect of type of therapy; cP-value relative to interaction term (time×therapy). dSignificant after FDR correction.
Figure 1 Central macular thickness modifications during time  Central foveal and parafoveal thickness modifications during time in the DEX 
group and RBZ group.
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DISCUSSION
Management of DR and its most common complications, such 
as DME, have improved with the development of different 
intravitreal drugs[4-8]. 
Intravitreal treatment of anti-VEGF, specifically targeting the 
VEGF and corticosteroids with their action of blockage the 
inflammatory mediators’ production, are largely widespread in 
the treatment of the DME condition[25]. 
Ranibizumab, a monoclonal anti-VEGF antibody fragment, is 
a safe treatment for DME with the early effects detectable as 
early as 7d after the first injection[9-11,26].
Similarly, dexamethasone, an anti-inflammatory agent approved 
by Food and Drug Administration in 2014 for intravitreal 
treatment, represents an efficacy DME treatment[27]. 
In our retrospective 6-month follow-up study no significant 
difference in terms of morphological and functional parameters 
was found between the two groups that underwent DEX and 
RBZ for DME treatment.
CMT showed a significant decrease in both groups compared 
to preoperative values. Patients treated with DEX showed 
a tendency to a higher decrease in comparison with RZB in 
the short-term period. In DEX group, the greatest reduction 
of foveal CMT was observed at 2mo. Conversely, in RZB 
group the greatest reduction of foveal CMT was detected 
at 120d. The effect peak of the dexamethasone implant 
has been already previously reported to be at 30d with a 
mean duration of the treatment being at 4mo[28]. Several 
studies have already demonstrated DEX efficacy in DME 
improvement[6,29]. It has been described 34% of CMT reduction 
at 30d after DEX implantation[16]. Similarly, in literature, the 
ranibizumab efficacy in CMT decrease of DME patients has 
been reported[30]. Callanan et al have compared dexamethasone 
Figure 2 OCTA images of the SCP (A and B, left panel), DCP (A and B, middle panel) and CC (A and B, right panel)  At baseline (A) 
vessel rarefaction surrounding the foveal avascular zone in the SCP and DCP, microaneurysms and diffuse vessel rarefaction in the DCP and 
focal areas with no apparent flow in the CC can be observed; corresponding structural SD-OCT images centred on the fovea (A and B, left, 
middle and right panel with overlying segmentation bands at the level of the SCP, DCP and CC, respectively) show increased retinal thickness 
due to cystoid macular edema and presence of subretinal fluid. After a loading dose of ranibizumab injection (B) a restoration of vessel density 
mainly in the DCP can be observed with corresponding resolution of macular edema and partial resolution of subretinal fluid. 
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Figure 3 OCTA images of the SCP (A and B, left panel), DCP (A and B, middle panel) and CC (A and B, right panel)  At baseline (A) 
vessel rarefaction surrounding the foveal avascular zone in the SCP and DCP, microaneurysms and diffuse vessel rarefaction in the DCP and 
focal areas with no apparent flow in the CC can be observed; corresponding structural SD-OCT images centred on the fovea (A and B, left, 
middle and right with overlying segmentation bands at the level of the SCP, DCP and CC, respectively) show increased retinal thickness due to 
cystoid macular edema and presence of subretinal fluid. After dexamethasone implant (B) a restoration of vessel density mainly in the DCP can 
be observed with corresponding resolution of macular edema and subretinal fluid.
with ranibizumab for the treatment of DME and demonstrated 
that the mean decrease in CMT from baseline was greater 
with the corticosteroids than the anti-VEGF at 1 and 2mo 
after injections[30]. In our study the re-treatment rate in patients 
treated with anti-VEGF injections was higher than those 
treated with DEX implantation. A three-year randomized 
sham-controlled trial reported a mean of 4-5 injections over 3y 
in DME patients treated with DEX[6]. Similarly to our findings, 
the Bevordex study[31] reported a comparison between anatomic 
and functional outcomes using DEX and bevacizumab during 
over 12-month follow-up. Anatomic findings were significantly 
better in patients treated with DEX with fewer injections 
(mean of 2.7 injections) compared to patients treated with the 
anti-VEGF (8.6 injections).
However, the final CMT was 300.1±26.7 µm in DEX group 
and 250.2±28.7 µm in the RZB group at 180d in our series 
thus probably leading to earlier retreatment in the DEX group.
Using OCTA analysis, we also investigated retinal superficial 
and deep vessel densities and CC density in both treatment 
groups. Nowadays, in clinical practice routinely use of OCTA 
allows for a better and precise evaluation of the microvascular 
retinal changes in DR and DME patients[16,32]. Some studies 
have already reported retinal capillary network and CC 
Figure 4 Kaplan-Meier curve of re-treatment according to group 
Continuous line is relative to patients in the RBZ group while dotter 
line is relative to patients in DEX group.
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Table 3 Two-way ANOVA for repeated measures of morphological parameters from baseline to 180d after therapy
Variable Group Baseline 30d 60d 90d 120d 150d 180d Pa Pb Pc
No. of eyes (DEX/RZB group) 25/25 25/25 25/25 25/12 14/12 13/10 13/9
SCPD (µm)
Whole DEX group 40.1±4.2 40.8±3.0 41.4±3.5 41.5±2.9 41.1±3.2 39.7±0.1 39.8±1.1 0.077 0.069 0.035
RZB group 39.8±4.4 40.7±6.2 42.1±3.4 43.2±4.4 45.2±3.6 45.5±3.1 45.7±3.1
Fovea DEX group 29.3±5.2 25.2±7.2 23.4±8.9 28.0±8.6 28.1±2.9 28.1±1.8 28.0±1.9 0.188 0.582 0.701
RZB group 26.8±5.8 27.2±7.1 25.3±5.2 28.6±5.0 26.3±7.1 25.6±6.0 25.0±7.5
Parafovea DEX group 41.3±4.3 41.0±5.3 41.7±5.0 40.8±3.3 41.2±3.4 40.7±1.3 41.3±1.1 0.059 0.088 0.040
RZB group 41.5±4.9 43.0±5.0 44.8±2.9 46.0±3.1 46.1±2.7 46.5±2.4 47.1±3.1
Parasuperior DEX group 40.0±5.8 42.2±5.1 42.3±5.0 41.1±3.3 41.9±3.3 40.7±.2.1 40.5±1.8 0.478 0.074 0.285
RZB group 41.3±5.1 43.4±5.4 44.5±3.9 46.0±3.0 45.1±3.7 46.0±2.9 46.1±3.9
Parainferior DEX group 41.0±6.1 42.8±4.3 40.4±4.1 41.2±3.9 41.5±3.8 40.7±0.2 41.1±0.5 0.585 0.028 0.023
RZB group 40.8±5.0 43.1±5.0 45.2±2.9 46.5±2.7 46.9±3.0 47.2±3.1 46.7±3.1
DCPD (µm)
Whole DEX group 45.4±5.1 48.3±3.8 47.2±4.4 43.0±6.2 46.5±5.7 46.5±3.1 46.4±2.7 0.482 0.788 0.344
RZB group 45.9±5.1 47.5±5.1 47.7±4.9 50.0±4.5 49.1±3.5 49.3±2.9 49.0±3.2
Fovea DEX group 19.8±7.4 26.1±8.0 24.8±6.0 27.1±6.1 27.5±8.2 27.6±8.0 27.7±7.4 0.001d 0.821 0.199
RZB group 20.7±7.7 26.2±8.0 24.4±7.2 28.8±7.0 27.8±10.4 27.2±6.4 27.4±7.0
Parafovea DEX group 48.3±3.9 50.8±4.0 48.4±4.0 47.4±5.1 48.4±6.0 47.8±3.9 48.1±3.8 0.622 0.654 0.199
RZB group 47.7±4.9 49.1±6.4 49.4±4.8 51.3±4.5 50.2±3.1 50.3±4.0 50.7±4.0
Parasuperior DEX group 46.5±6.0 50.8±4.6 49.4±4.0 47.3±6.3 50.1±4.7 47.8±3.1 47.4±2.2 0.301 0.901 0.284
RZB group 48.8±4.9 50.4±6.8 49.7±6.0 51.0±4.4 51.4±4.4 50.8±4.0 49.9±4.3
Parainferior DEX group 47.5±5.0 50.3±4.9 47.7±5.0 45.4±5.4 47.1±7.2 47.7±4.4 47.3±5.0 0.411 0.561 0.310
RZB group 47.7±3.9 48.7±5.0 49.1±4.4 51.3±4.2 50.1±3.8 51.2±3.0 51.2±4.0
CCD (µm)
Whole DEX group 63.0±1.8 65.0±1.8 65.5±1.5 64.4±1.8 60.8±6.8 57.7±8.4 58.0±9.0 0.511 0.399 0.301
RZB group 61.3±7.0 64.5±2.2 64.0±2.0 65.3±2.2 65.5±1.7 65.5±1.4 65.5±1.3
Fovea DEX group 60.8±5.7 65.9±2.8 65.4±5.4 64.5±1.8 59.3±8.0 54.8±6.0 55.4±7.1 0.522 0.822 0.598
RZB group 61.4±6.2 63.7±2.5 62.7±5.0 64.7±4.0 63.3±3.4 64.9±1.9 65.2±2.8
Parafovea DEX group 63.0±3.3 64.8±1.9 65.1±1.8 64.4±1.4 58.7±7.1 57.8±12.7 57.3±11.0 0.488 0.374 0.362
RZB group 61.5±6.0 63.4±3.1 63.9±2.0 65.2±2.7 65.8±1.9 66.8±1.5 66.9±1.7
Parasuperior DEX group 62.0±2.1 64.7±1.9 65.9±1.4 63.8±1.9 61.9±6.4 56.7±12.4 56.8±9.7 0.188 0.878 0.154
RZB group 59.9±8.8 61.8±2.2 63.8±2.7 65.1±3.8 65.3±2.7 64.5±4.3 64.7±2.3
Parainferior DEX group 62.0±3.3 65.0±1.7 65.4±1.9 65.0±2.0 58.9±7.7 57.2±10.0 58.0±8.9 0.502 0.368 0.448
RZB group 61.5±6.3 63.2±2.5 63.6±2.4 65.5±2.9 65.6±1.8 65.9±1.6 66.2±1.7
Data are expressed as mean and standard deviation. CMT: Central macular thickness; SCPD: Superior capillary plexus density; DCPD: Deep 
capillary plexus density; CCD: Choriocapillaris density. aP-value relative to effect of period; bP-value relative to effect of type of therapy; 
cP-value relative to interaction term (time×therapy). dSignificant after FDR correction.
modifications in DR patients, such as a decrease of vessel 
density and a significant decrease of capillary perfusion density 
values as retinopathy progresses[32-33]. It has been described that 
the reduction of vessel density was more evident in the DCP 
compared to the superficial plexus[32-33].
In our study, deep vessel density increased significantly after 
both RZB and DEX injections; on the contrary, we did not 
find significant modifications of foveal and parafoveal retinal 
superficial vascular density after the two treatments.
In several studies it has been observed that in DME patients 
DCP is severely damaged showing reduced density, ectatic 
vessels, no flow areas corresponding to cysts[32,34-35]. In 
particular, sites of macular edema are mainly localized in the 
deep plexus in regions of reduced or absent flow.
It has been speculated that DCP could be a potential predictor 
of the effectiveness of the DME treatment. Lee et al[32] found 
a significant correlation between the status of DCP and the 
therapy response. We hypothesize that the modification of 
vessel density after treatment could be related to two factors: 
disappearance of macular edema and steroid and anti-VEGF 
effect on vessel diameter.
The modification of vessel density in DR complicated by DME 
could be in part related to vessel displacement by intraretinal 
fluid particularly when retinal cysts are present, thus edema 
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reduction or resolution could modify the vessel distribution. 
In addition, vessel caliber could change due to the drug effect 
thus influencing vessel density assessment. The blockage of 
VEGF due to intravitreal steroid such as dexamethasone or 
anti-VEGF injections can lead to a reduction of arteriolar or 
venular vessel diameter with a resolution or improvement of 
macular edema[36-37]. 
The CCD after treatment did not show any significant increase 
in both groups.
Capillary perfusion density has been found reduced in patients 
suffering from DR with greater reduction at increasing disease 
severity[33]. As previously reported in retinal vein occlusion 
complicated by macular edema it can be hypothesized that 
overlying retinal edema could attenuate the OCT signal of the 
CC[38]. A role of anti-VEGF and dexamethasone in influencing 
directly CCD could be considered and investigated. 
Regarding functional parameters, overall retinal sensitivity 
detected with microperimetry increased significantly after 
therapy. It is probably related to a rearrangement of foveal 
architecture and to the status of photoreceptors, also after the 
improvement of DME[39]. 
On the contrary, the BCVA showed a statistically significant 
increase in both groups of treatment, with the highest gain at 
60d post implant in the patients treated with DEX. 
This study has some limitations such as the relatively small 
sample of eyes examined presenting only no proliferative 
moderate DR stage, the short follow-up and the retrospective 
nature.
In conclusion, RBZ and DEX appeared both safe and effective 
therapies for DME. The corticosteroid medication showed an 
earlier short-term effect with a lower retreatment rate compared 
to ranibizumab. Nevertheless, the two different intravitreal 
treatments both allowed a fast improvement of the pathology 
in terms of anatomical and functional outcomes.
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